Jaime-Pérez JC, López-Razo ON, Marfil- Rivera LJ, Herrera-Garza JL, González-Llano O, Gómez-Almaguer D

Language: Spanish
References: 20
Page: 131-137
PDF size: 380.65 Kb.

ABSTRACT

Background and Objective: Immune Thrombocytopenic Purpura (ITP) is a disorder characterized by the production of anti-platelet antibodies leading to platelet destruction. There is a lack of information regarding the characteristics of ITP patients in northeast México.
Material and Methods: All patients diagnosed with ITP at the “Dr. José Eleuterio González” University Hospital during a 5-year period were included. The clinical presentation, treatment and outcome for children and adults, as well as Relapse Free Survival (RFS) were determined. Hazard Ratio (HR) for relapse was estimated by univariate Cox analysis.
Results: 72 patients were included, 35 were <16 years, 53.4% belonged to the male gender and 45.7% were females. Thirty-seven patients were ≥16 years, 29.7% males and 70.3% females. 43% of the children had a recent history of infectious disease. The one-year Relapse Free Survival (RFS) for children and adults was 74.6% and 51.2%, respectively P= 0.656. 45.5 of adults did not comply with follow-up visits. 22.9% of those <16 years (n=8) and 37.8% of adults (n=14) relapsed; the platelet count at relapse was 15.10x109/L (SD 8.10) on patients <16 years of age and 15.46x109/L (SD 14.13) in adults. No deaths occurred.
Conclusion: Although the clinical presentation, diagnosis, treatment and outcome of the ITP in children and adults during the period of the study was similar to published data some interesting differences in the clinical course were documented

REFERENCES

1. Marfil Rivera LJ. Enfermedades hemorrágicas por defectos vasculares y plaquetarios. En: Hematología. La sangre y sus enfermedades. Jaime Pérez JC, Gómez Almaguer D (editores). México: McGraw-Hill Interamericana, 2012;165-171.

2. Jaime Pérez JC. Púrpura trombocitopénica inmunológica. En: Hematología. La sangre y sus enfermedades. Jaime Pérez JC, Gómez Almaguer D (editores). México: McGraw-Hill Interamericana, 2012;187-192.

3. Thienelt CD, Calverley DC. Thrombocytopenia Caused by Immunologic Platelet Destruction In: Wintrobe’s Clinical Hematology. Greer JP, Foerster J, Rodgers GM, Paraskevas F, Glader B, Arber DA, Means RT (editores). 12th ed. Philadelphia: Lippincot William and Wilkins, 2009;1292-1313.

4. Cines DB, Bussel JB, Liebman HA, Luning-Prak ET. ITP syndrome: pathogenic and clinical diversity. Blood 2009;113:6511- 6521.

5. Terrel DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JM. Determining a definite diagnosis of primary immune thrombocytopenia by medical record review. Am J Hematol 2012;87:843-847.

6. Kuhne T, Imbach P. Management of children and adolescents with primary immune thrombocytopenia: controversies and solutions. Vox Sanguinis 2013;154:55-66.

7. Rodeghiero F, Stasi R, Gemsheimer T, Michael M, et al. Standardization of terminology, definitions and outcome criteria in immune trombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386-2393.

8. Wilson DB. Acquired platelet defects. En: Hematology of Infancy and Childhood. Nathan DG, Orkin SH, Ginsburg D, Look AT (editores). 6th ed. Philadelphia: Saunders, 2003;1597-1621.

9. Ambriz-Fernández R, Martínez-Murillo C, Quintana-González S, Collazo Jaloma J, Bautista-Juárez J. Fc Receptor Blockade in Patients with Refractory Chronic Immune Thrombocytopenic Purpura with Anti-D IgG. Arch Med Res 2002;33:536-540.

10. García Chávez J, Majluf-Cruz A, Montiel-Cervantes L, García- Ruiz Esparza M, Vela-Ojeda J. The Mexican Hematology Study Group. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis. Ann Hematol 2007;86:871-877.

11. Gómez-Almaguer D, Solano-Genesta M, Tarín-Arzaga L, Herrera-Garza JL, Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, Jaime-Pérez JC. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoinmune cytopenias. Blood 2010;116:4783-4785.

12. Pita-Ramírez L, Hurtado-Monroy R, Labardini-Méndez J. Tratamiento de la púrpura trombocitopénica idiopática crónica refractaria: experiencia de diez años en el Instituto Nacional de la Nutrición Salvador Zubirán. Rev Invest Clin 1992;44:501-506.

13. Covarrubias Espinoza R, Sotelo Cruz N, Hurtado Valenzuela JG, Púrpura trombocitopénica autoinmune. Informe de 108 casos. Bol Med Hosp Infant Mex 2004;61:119-127.

14. Gutiérrez-Espindola GR, Morales-Polanxo MR, Guerrero- -Rivera S, Talavera JO, Sanchesz Valle E, Gómez-Morales E, Pizzuto-Chávez J. High Doses of Dexamethasone in Adult Patients with Idiopathic Thrombocytopenic Purpura. Arch Med Res 2003;34:31-34.

15. Georges JN, El-Harake MA, Raskob GE, Chronic Idiopathic Thrombocytopenic Purpura. N Engl J Med 1994;331:1207- 1211.

16. Portielje JE, Westendrop RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;97:2549-2554.

17. Stasi R, Provan D. Helicobacter pylori and Chronic ITP. Am Soc Hematol Educ Program 2008;206-211.

18. Kuwana M, Ikeda Y. Helicobacter pylori and Immune Thrombocytopenic Purpura: Unsolved Questions and Controversies. Int J Hematol 2006;84:309-315.

19. Zaja F, Volpetti S, Chiozzotto M, Puglisi S, Isola M, Fanin R. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia. Am J Hematol 2012;87:886-889.

20. Altomare I, Wasser J, Pullarkat V. Bleeding and mortality outcomes in ITP clinical trials: A review of thrombopoietin mimetics data. Am J Hematol 2012;87:984-987.